Actelion: Another strong quarter and two upcoming launches

BUY, Fair Value CHF67 (+1%)

News published on October Thursday 17, 2013
Share on

Momentum still looks very good for Actelion. Ahead of the expected approval of Opsumit (macitentan) in the US tomorrow, Actelion has issued strong quarterly figures today, a touch above expectations. Sales were up 4% in local currencies for the first nine months, up from 3% in H1 whereas Core EPS sustained the high level of growth already reported in the first half i.e. +21%. We were anticipating a slowdown based on an increased level of investments in R&D (entry of cadazolid in phase III) and in SG&A (preparation for launch of Opsumit). Admittedly operating expenses were slightly on the upside, but revenues were a bit higher than expected whereas share buybacks helped the bottom line. In all, this was another very good quarter. All lights are at green for Actelion!


Full report available to subscribers
Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities